FDA Approves New Dosing Option for CSL Behring's Hizentra(R)

New Label Supports Individualized Therapy Through Greater Dosing Flexibility From Daily to Once Every Two Weeks (Biweekly); Underscores CSL Behring's Commitment to Improving Patients' Lives KING OF PRUSSIA, Pa., Feb. 2, 2015 -- (Healthcare Sales & Marke... Biopharmaceuticals, FDACSL Behring, Hizentra, Immune Globulin, immunodeficiency
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news